Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 2/2024

Open Access 16-02-2024 | Heart Failure | Review

Digital Solutions to Optimize Guideline-Directed Medical Therapy Prescriptions in Heart Failure Patients: Current Applications and Future Directions

Authors: Jelle P. Man, Joanna Klopotowska, Folkert W. Asselbergs, M. Louis Handoko, Steven A. J. Chamuleau, Mark J. Schuuring

Published in: Current Heart Failure Reports | Issue 2/2024

Login to get access

Abstract

Purposeof Review

Guideline-directed medical therapy (GDMT) underuse is common in heart failure (HF) patients. Digital solutions have the potential to support medical professionals to optimize GDMT prescriptions in a growing HF population. We aimed to review current literature on the effectiveness of digital solutions on optimization of GDMT prescriptions in patients with HF.

Recent Findings

We report on the efficacy, characteristics of the study, and population of published digital solutions for GDMT optimization. The following digital solutions are discussed: teleconsultation, telemonitoring, cardiac implantable electronic devices, clinical decision support embedded within electronic health records, and multifaceted interventions. Effect of digital solutions is reported in dedicated studies, retrospective studies, or larger studies with another focus that also commented on GDMT use. Overall, we see more studies on digital solutions that report a significant increase in GDMT use. However, there is a large heterogeneity in study design, outcomes used, and populations studied, which hampers comparison of the different digital solutions. Barriers, facilitators, study designs, and future directions are discussed.

Summary

There remains a need for well-designed evaluation studies to determine safety and effectiveness of digital solutions for GDMT optimization in patients with HF. Based on this review, measuring and controlling vital signs in telemedicine studies should be encouraged, professionals should be actively alerted about suboptimal GDMT, the researchers should consider employing multifaceted digital solutions to optimize effectiveness, and use study designs that fit the unique sociotechnical aspects of digital solutions. Future directions are expected to include artificial intelligence solutions to handle larger datasets and relieve medical professional’s workload.
Literature
1.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599–726.PubMedCrossRef
2.
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368–76.PubMedCrossRef
3.
Hsiao R, Greenberg B. Neprilysin Inhibition as a PARADIGM shift in heart failure therapy. Curr Heart Fail Rep. 2016;13:172–80.PubMedCrossRef
4.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;ehad195.
5.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10:73–84.PubMedCrossRef
6.
Xiang B, Yu Z, Zhou X. Comparative efficacy of medical treatments for chronic heart failure: a network meta-analysis. Front Cardiovasc Med. 2021;8:787810.PubMedCrossRef
7.
Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021;23:882–94.PubMedCrossRef
8.
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;S0140–6736(22):02076–81.
9.
Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci. 2022;7:504–17.PubMedPubMedCentralCrossRef
10.
Shen L, Jhund PS, Docherty KF, Vaduganathan M, Petrie MC, Desai AS, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J. 2022;43:2573–87.PubMedCrossRef
11.
Greene SJ, Butler J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed. JAMA Cardiol. 2021;6:743–4.PubMedCrossRef
12.
Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, Thuresson M, Bozkurt B. Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail. 2022;S2213–1779(22)00508-X.
13.
Brunner-La Rocca H-P, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma H-J, Westendorp PH, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Heart Fail. 2019;7:13–21.PubMedCrossRef
14.
González-Juanatey JR, Cinza SS. Clinician-to-clinician electronic consultation in cardiology is also a digital health technology for cardiovascular care. Eur Heart J Digit Health. 2023;4:69–70.PubMedPubMedCentralCrossRef
15.
Jensen MT, Treskes RW, Caiani EG, Casado-Arroyo R, Cowie MR, Dilaveris P, et al. ESC working group on e-cardiology position paper: use of commercially available wearable technology for heart rate and activity tracking in primary and secondary cardiovascular prevention—in collaboration with the European Heart Rhythm Association, European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professionals, Patient Forum, and the Digital Health Committee. Europ Heart J - Digital Health. 2021;2:49–59.CrossRef
16.
Kauw D, Koole MAC, Winter MM, Dohmen DAJ, Tulevski II, Blok S, et al. Advantages of mobile health in the management of adult patients with congenital heart disease. Int J Med Inform. 2019;132:104011.PubMedCrossRef
17.
Anker SD, Koehler F, Abraham WT. Telemedicine and remote management of patients with heart failure. Lancet. 2011;378:731–9.PubMedCrossRef
18.
19.
Ahmed S, Kelly YP, Behera TR, Zelen MH, Kuye I, Blakey R, et al. Utility, Appropriateness, and content of electronic consultations across medical subspecialties. Ann Intern Med. 2020;172:641–7.PubMedCrossRef
20.
Takahashi EA, Schwamm LH, Adeoye OM, Alabi O, Jahangir E, Misra S, et al. An overview of telehealth in the management of cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2022;146:e558–68.PubMedCrossRef
21.
22.
van Ommen F, Coenen P, Malekzadeh A, de Boer AGEM, Greidanus MA, Duijts SFA. Interventions for work participation of unemployed or work-disabled cancer survivors: a systematic review. Acta Oncol. 2023;62:753–64.PubMedCrossRef
23.
Ros R, Bjarnason E, Runeson P. A machine learning approach for semi-automated search and selection in literature studies [Internet]. In: Proceedings of the 21st International Conference on Evaluation and Assessment in Software Engineering. New York, NY, USA: Assoc Comput Mach. 2017;118–127. Available from: https://​doi.​org/​10.​1145/​3084226.​3084243
24.
van de Schoot R, de Bruin J, Schram R, Zahedi P, de Boer J, Weijdema F, et al. An open source machine learning framework for efficient and transparent systematic reviews. Nature Machine Intelligence. 2021;3:125–33.CrossRef
25.
Guasti L, Dilaveris P, Mamas MA, Richter D, Christodorescu R, Lumens J, et al. Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Geriatric Cardiology, the ESC Digital Health Committee and the ESC Working Group on e-Cardiology. ESC Heart Fail. 2022;9:2808–22.PubMedPubMedCentralCrossRef
26.
Bhatt AS, Varshney AS, Nekoui M, Moscone A, Cunningham JW, Jering KS, et al. Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. Eur J Heart Fail. 2021;23:1191–201.PubMedCrossRef
27.
Bhatt AS, Varshney AS, Moscone A, Claggett BL, Miao ZM, Chatur S, et al. Virtual care team guided management of patients with heart failure during hospitalization. J Am Coll Cardiol. 2023;81:1680–93.PubMedCrossRef
28.
Rao VN, Shah A, McDermott J, Barnes SG, Murray EM, Kelsey MD, et al. In-hospital virtual peer-to-peer consultation to increase guideline-directed medical therapy for heart failure: a pilot randomized trial. Circ Heart Fail. 2023;16:e010158.PubMed
29.
Sammour Y, Main ML, Austin BA, Magalski A, Sperry BW. Outpatient management of guideline-directed medical therapy for heart failure using telehealth: a comparison of in-office, video, and telephone visits. J Card Fail. 2022;28:1222–6.PubMedCrossRef
30.
Wakefield BJ, Holman JE, Ray A, Scherubel M, Burns TL, Kienzle MG, et al. Outcomes of a home telehealth intervention for patients with heart failure. J Telemed Telecare. 2009;15:46–50.PubMedCrossRef
31.
Yuan N, Botting PG, Elad Y, Miller SJ, Cheng S, Ebinger JE, et al. Practice patterns and patient outcomes after widespread adoption of remote heart failure care. Circ Heart Fail. 2021;14:e008573.PubMedPubMedCentralCrossRef
32.
Antonicelli R, Testarmata P, Spazzafumo L, Gagliardi C, Bilo G, Valentini M, et al. Impact of telemonitoring at home on the management of elderly patients with congestive heart failure. J Telemed Telecare. 2008;14:300–5.PubMedCrossRef
33.
Artanian V, Ross HJ, Rac VE, O’Sullivan M, Brahmbhatt DH, Seto E. Impact of remote titration combined with telemonitoring on the optimization of guideline-directed medical therapy for patients with heart failure: internal pilot of a randomized controlled trial. JMIR Cardio. 2020;4:e21962.PubMedPubMedCentralCrossRef
34.
Massot M, Itier R, Galinier M, Roncalli J, Fournier P, Ayot S, et al. Ultra-fast remote up-titration of heart failure treatment: a safe, efficient and feasible protocol. Europ Heart J. 2022;43(544):ehac544.945.CrossRef
35.
Ware P, Ross HJ, Cafazzo JA, Boodoo C, Munnery M, Seto E. Outcomes of a heart failure telemonitoring program implemented as the standard of care in an outpatient heart function clinic: pretest-posttest pragmatic study. J Med Internet Res. 2020;22:e16538.PubMedPubMedCentralCrossRef
36.
Brahmbhatt DH, Ross HJ, O Sullivan M, Artanian V, Rac VE, Seto E. Use of a remote telemonitoring platform significantly improves medication optimisation in heart failure patients. Eur Heart J. 2022;43:ehac544.1094.
37.
Giordano A, Zanelli E, Scalvini S. Home-based telemanagement in chronic heart failure: an 8-year single-site experience. J Telemed Telecare. 2011;17:382–6.PubMedCrossRef
38.
Samsky MD, Leverty R, Gray JM, Davis A, Fisher B, Govil A, et al. Patient perspectives on digital interventions to manage heart failure medications: the VITAL-HF pilot. J Clin Med. 2023;12:4676.PubMedPubMedCentralCrossRef
39.
Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan B-A, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392:1047–57.PubMedCrossRef
40.
McLachlan A, Aldridge C, Morgan M, Lund M, Gabriel R, Malez V. An NP-led pilot telehealth programme to facilitate guideline-directed medical therapy for heart failure with reduced ejection fraction during the COVID-19 pandemic. N Z Med J. 2021;134:77–88.PubMed
41.
Romero E, Yala S, Sellers-Porter C, Lynch G, Mwathi V, Hellier Y, et al. Remote monitoring titration clinic to implement guideline-directed therapy for heart failure patients with reduced ejection fraction: a pilot quality-improvement intervention. Front Cardiovasc Med. 2023;10:1202615.PubMedPubMedCentralCrossRef
42.
Wong CK, Un KC, Zhou M, Cheng Y, Lau YM, Shea PC, et al. Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. Eur Heart J Digit Health. 2022;3:284–95.PubMedPubMedCentralCrossRef
43.
Dierckx R, Cleland JG, Pellicori P, Zhang J, Goode K, Putzu P, et al. If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment? J Telemed Telecare. 2015;21:331–9.PubMedCrossRef
44.
Adamson PB, Abraham WT, Stevenson LW, Desai AS, Lindenfeld J, Bourge RC, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circ Heart Fail. 2016;9: e002600.PubMedCrossRef
45.
Srivastava PK, DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, et al. Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients. JACC Heart Fail. 2021;9:28–38.PubMedCrossRef
46.
Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023;401:2113–23.PubMedCrossRef
47.
Hernandez AF, Albert NM, Allen LA, Ahmed R, Averina V, Boehmer JP, et al. Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - phase I evaluation of the integration and safety of the heartlogic multisensor algorithm in patients with heart failure. J Card Fail. 2022;28:1245–54.PubMedCrossRef
48.
D’Onofrio A, Stabile G, Capucci A, Amellone C, De Simone A, Leoni L, et al. Association between remote implantable cardioverter defibrillator monitoring and beta-blocker utilization: an analysis from the EFFECT study. J Telemed Telecare. 2016;22:383–90.PubMedCrossRef
49.
Allen LA, Venechuk G, McIlvennan CK, Page RL, Knoepke CE, Helmkamp LJ, et al. An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial. Circulation. 2021;143:427–37.PubMedCrossRef
50.
Ghazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, Martin M, O’Connor KD, et al. Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial. J Am Coll Cardiol. 2022;79:2203–13.PubMedCrossRef
51.
Fuery MA, Kadhim B, Samsky MD, Freeman JV, Clark K, Desai NR, et al. Electronic health record embedded strategies for improving care of patients with heart failure. Curr Heart Fail Rep. 2023;20:280–6.PubMedCrossRef
52.
McCarren M, Furmaga E, Jackevicius CA, Sahay A, Coppler TL, Katzianer J, et al. Improvement of guideline β-blocker prescribing in heart failure: a cluster-randomized pragmatic trial of a pharmacy intervention. J Card Fail. 2013;19:525–32.PubMedCrossRef
53.
Mukhopadhyay A, Reynolds HR, Phillips LM, Nagler AR, King WC, Szerencsy A, et al. Cluster-randomized trial comparing ambulatory decision support tools to improve heart failure care. J Am Coll Cardiol. 2023;81:1303–16.PubMedPubMedCentralCrossRef
54.
Ghazi L, Yamamoto Y, Fuery M, O’Connor K, Sen S, Samsky M, Riello RJ, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. Eur Heart J. 2023;ehad512.
55.
Ahmad T, Desai NR, Yamamoto Y, Biswas A, Ghazi L, Martin M, et al. Alerting clinicians to 1-year mortality risk in patients hospitalized with heart failure: the REVEAL-HF randomized clinical trial. JAMA Cardiol. 2022;7:905–12.PubMedPubMedCentralCrossRef
56.
Man JP, Dijkgraaf MGW, Handoko ML, de Lange FJ, Winter MM, Schijven MP, Stienen S, Meregalli P, Kok WEM, Kuipers DI, van der Harst P, Koole MAC, Chamuleau SAJ, Schuuring MJ. Digital consults to optimize guideline-directed therapy: design of a pragmatic multicenter randomized controlled trial. ESC Heart Fail. 2024;11:560–9.PubMedCrossRef
57.
Gulizia MM, Orso F, Mortara A, Lucci D, Aspromonte N, De Luca L, et al. BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines. Eur J Heart Fail. 2022;24:2078–89.PubMedCrossRef
58.
Lynch KA, Ganz DA, Saliba D, Chang DS, de Peralta SS. Improving heart failure care and guideline-directed medical therapy through proactive remote patient monitoring-home telehealth and pharmacy integration. BMJ Open Qual. 2022;11:e001901.PubMedPubMedCentralCrossRef
59.
Slade J, Lee M, Park J, Liu A, Heidenreich P, Allaudeen N. Harnessing the potential of primary care pharmacists to improve heart failure management. Jt Comm J Qual Patient Saf. 2022;48:25–32.PubMed
60.
Rahimi K, Nazarzadeh M, Pinho-Gomes A-C, Woodward M, Salimi-Khorshidi G, Ohkuma T, et al. Home monitoring with technology-supported management in chronic heart failure: a randomised trial. Heart. 2020;106:1573–8.PubMedCrossRef
61.
Verma A, Fonarow GC, Hsu JJ, Jackevicius CA, Vaghaiwalla Mody F, Nguyen A, et al. DASH-HF study: a pragmatic quality improvement randomized implementation trial for patients with heart failure with reduced ejection fraction. Circ Heart Fail. 2023;16:e010278.PubMedCrossRef
62.
Barsom EZ, Meijer HAW, Blom J, Schuuring MJ, Bemelman WA, Schijven MP. Emergency upscaling of video consultation during the COVID-19 pandemic: contrasting user experience with data insights from the electronic health record in a large academic hospital. Int J Med Inform. 2021;150:104463.PubMedPubMedCentralCrossRef
63.
Schuuring MJ, Kauw D, Bouma BJ. COVID-19 pandemic: practical considerations on rapid initiation of remote care in chronic cardiac patients. Europ Heart J - Digital Health. 2020;1:8–9.CrossRef
64.
Hrynyschyn R, Prediger C, Stock C, Helmer SM. Evaluation methods applied to digital health interventions: what is being used beyond randomised controlled trials?-A scoping review. Int J Environ Res Public Health. 2022;19:5221.PubMedPubMedCentralCrossRef
65.
Soobiah C, Cooper M, Kishimoto V, Bhatia RS, Scott T, Maloney S, et al. Identifying optimal frameworks to implement or evaluate digital health interventions: a scoping review protocol. BMJ Open. 2020;10:e037643.PubMedPubMedCentralCrossRef
66.
de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–68.PubMedCrossRef
67.
Kauw D, Huisma PR, Medlock SK, Koole MAC, Wierda E, Abu-Hanna A, Schijven MP, Mulder BJM, Bouma BJ, Winter MM, Schuuring MJ. Mobile health in cardiac patients: an overview on experiences and challenges of stakeholders involved in daily use and development. BMJ Innovations. 2020;6(4):184–91. https://​doi.​org/​10.​1136/​bmjinnov-2019-000418.CrossRef
68.
Stevenson LW, Ross HJ, Rathman LD, Boehmer JP. Remote monitoring for heart failure management at home. J Am Coll Cardiol. 2023;81:2272–91.PubMedCrossRef
69.
70.
Victoria-Castro AM, Martin M, Yamamoto Y, Ahmad T, Arora T, Calderon F, et al. Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: design, rationale and implementation. Clin Cardiol. 2022;45:839–49.PubMedPubMedCentralCrossRef
Metadata
Title
Digital Solutions to Optimize Guideline-Directed Medical Therapy Prescriptions in Heart Failure Patients: Current Applications and Future Directions
Authors
Jelle P. Man
Joanna Klopotowska
Folkert W. Asselbergs
M. Louis Handoko
Steven A. J. Chamuleau
Mark J. Schuuring
Publication date
16-02-2024
Publisher
Springer US
Keyword
Heart Failure
Published in
Current Heart Failure Reports / Issue 2/2024
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-024-00649-x

Other articles of this Issue 2/2024

Current Heart Failure Reports 2/2024 Go to the issue

Review

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions—Part II: Combination Therapy

Review

Heart Failure: a Punch from the Gut

Review

Fabry Disease: Cardiac Implications and Molecular Mechanisms

Review

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions – Part I: Loop Diuretics

Review

Contrast Echocardiography in Heart Failure: Update 2023

Review

Evolutions in Combined Heart-Kidney Transplant
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits